Call for cancer investigators for Nevasic trial

A UK-based biotechnology company are seeking investigators in the field of cancer to run a fourth trial project for Nevasic, a product that uses specially constructed audio signals to generate an antiemetic reaction.

DAVAL Ltd has successfully concluded three phases of research in three areas: travel or motion sickness, sickness associated with pregnancy and cancer treatment with mastectomy patients.

The fourth Nevasic project would be run independently by NIHR investigators to ensure there is no conflict of interest. For more information regarding this product open this presentation or visit www.nevasic.com

If you are interested in this opportunity complete the expression of interest form and return to Lauren Chapman lauren.chapman@nihr.ac.uk by cop Tuesday 2 September 2014.

Nevasic is an audio programme which uses audio pulses and frequencies in the attempt to provide relief from symptoms of nausea and vomiting in connection with travel or motion sickness, pregnancy sickness and morning sickness.